GlassScriptPhysician profile
William T Kendrick
NPI 1407858632
$125,239.76
in general payments reported to CMS, 2019-2025
41 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $14K · 2021: $17K · 2022: $15K · 2023: $18K · 2024: $13K · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $4,600 · Travel and Lodging: $1,198 · Education: $193 · Consulting Fee: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,096.00 |
| Food and Beverage | $4,599.67 |
| Travel and Lodging | $1,197.93 |
| Education | $192.93 |
| Consulting Fee | $103.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $65,783.01 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $22,563.85 | 2021-2025 | |
| Akebia Therapeutics INC | $16,312.13 | 2019-2024 | Auryxia, Vafseo |
| Astrazeneca Pharmaceuticals LP | $15,806.07 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Otsuka America Pharmaceutical, INC. | $469.06 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $464.60 | 2019-2024 | Veltassa |
| Horizon Therapeutics Plc | $459.14 | 2019-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $442.90 | 2019-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $433.82 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $350.67 | 2019-2024 | Velphoro |
| Travere Therapeutics, INC. | $271.40 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $234.88 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $197.51 | 2021-2024 | Lupkynis |
| Cumberland Pharmaceuticals, INC. | $143.73 | 2021 | |
| Glaxosmithkline, LLC. | $123.19 | 2022-2024 | Benlysta, Jesduvroq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.